NCT00234364

Brief Summary

In a blinded echocardiographic study we investigate the frequency of valvular abnormalities in a group of Parkinson patients treated with either ergot derived dopamine agonists (pergolide and cabergoline) or non-ergot derived dopamine agonists (pramipexole and ropinirole). The ability to detect patients with valvular abnormalities by clinical approach is examined.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
155

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2005

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2005

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

October 4, 2005

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 7, 2005

Completed
1.9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2007

Completed
Last Updated

September 20, 2007

Status Verified

September 1, 2007

First QC Date

October 4, 2005

Last Update Submit

September 19, 2007

Conditions

Heart Valve DiseasesParkinson's DiseasePergolideFibrosis

Keywords

PergolideErgotamine derivatesValvular heart disease

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Parkinson patients who in the last year has been treated minimum 6 months with either ergotamine derivative or non-ergotamine derivative dopamine agonists (the latter included as controls)
  • Informed contests

You may not qualify if:

  • Control patients will be excluded if the have been treated with ergotamine derivates in the last 12 months or if the prior to that have had ergotamine derivates for more than 6 months
  • Patients with known valvular heart disease prior to the diagnosis of Parkinson

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Skejby Hospital

Aarhus, Aahus N, 8200, Denmark

Location

MeSH Terms

Conditions

Heart Valve DiseasesParkinson DiseaseFibrosis

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesParkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Vibeke G Rasmussen, MD

    Aarhus University Hospital Skejby

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
DEFINED POPULATION
Time Perspective
OTHER
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

October 4, 2005

First Posted

October 7, 2005

Study Start

March 1, 2005

Study Completion

September 1, 2007

Last Updated

September 20, 2007

Record last verified: 2007-09

Locations

DK(1)